Bioglutide Na-931 Cov txiaj ntsig hauv Multi-Receptor Activation

Cov tebchaw tshiab uas tsom ntau yambioglutide na-931 physiological txheej txheem nyob rau tib lub sij hawm yog tas li hloov chaw ntawm metabolic kev kawm. bioglutide na-931 yog ib kauj ruam loj rau hauv kev kawm ntawm ntau- receptor agonists vim nws ua haujlwm nrog GLP-1 thiab GIP receptors los ua cov teebmeem metabolic uas muaj zog dua ib leeg. Cov tuam txhab tshuaj, cov tuam txhab biotechnology, thiab cov tsev kawm tshawb fawb thoob plaws ntiaj teb tau xav txog cov txheej txheem kev ua haujlwm ob zaug vim tias nws muaj txoj hauv kev tshiab los kawm txog kev tswj hwm metabolic thiab tswj qhov hnyav.

Tshawb nrhiav seb yuav ua li cas bioglutide na-931 muab tso ua ke ntawm qib molecular pab peb nkag siab tias vim li cas cov molecule no tau dhau los ua qhov tseem ceeb hauv cov kev tshawb fawb txog metabolic niaj hnub no. Tsis zoo li feem ntau ib leeg -receptor agonists, qhov peptide analog binds zoo heev rau ob qho tib si incretin receptor systems. Qhov no tsim kom muaj kev sib koom ua ke ntawm lub cev muaj zog uas zoo li ib txwm muaj kev cuam tshuam ntawm metabolic tshaj li yav dhau los ntawm cov neeg sib tw kho mob. bioglutide na-931 muaj qhov tshwj xeeb pharmacological profile uas sib xyaw cov piam thaj txo qis ntawm kev ua kom GLP-1 txoj hauv kev nrog cov metabolism hauv boosting los ntawm activating GIP txoj kev. Cov kws tshawb fawb tshawb xyuas bioglutide na-931 tau sau tseg nws qhov tshwj xeeb pharmacological profile, uas sib txuas cov teebmeem uas dhau mus dhau ntawm kev ua kom cov receptors. Nws hloov cov txheej txheem metabolic uas tswj hwm lub zog sib npaug, kev faib khoom noj khoom haus, thiab kev hloov pauv hauv lub cev pleev.

 

Tom ntej: Bioglutide NA-931

1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
PE / Al foil hnab / ntawv lub thawv rau cov hmoov ntshiab
(2) Spot-On
(3) Kev daws teeb meem
(4) Poob
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
Khoom siv: BM-1-154
TIAB SA-931
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R & D Dept.-3

Peb muab bioglutide NA-931, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia thiab cov khoom lag luam.

Khoom siv:https://www.bloomtechz.com/synthetic-chemical/peptide/bioglutide-na-931.html

Ua li casbioglutide na-931 Txhawb Ntau -Receptor Activation?

Txoj kev bioglutide na-931 activates ntau receptors yog vim txoj kev nws cov qauv tshuaj tau ua tib zoo tsim. Cov kab mob peptide muaj qee qhov kev hloov pauv rau cov amino acids uas cia ob qho tib si GLP-1 thiab GIP receptor khi thaj tsam lees paub nws tib lub sijhawm. Qhov no ua rau muaj qhov sib npaug agonist profile uas tig rau ob txoj hauv kev yam tsis nyiam ib qho dhau ib qho.

Cov yam ntxwv ntawm cov qauv ua kom muaj kev sib koom ua ke ntawm Dual Receptor

bioglutide na-931's molecular qauv suav nrog kev hloov pauv mus rau qhov qub peptide qaum qaum uas ua rau nws ruaj khov dua thaum khaws nws lub peev xwm los khi thiab paub txog receptors. Cov kev hloov pauv rau cov qauv no suav nrog fatty acid conjugation, uas ua rau cov molecule nyob ntev dua thiab nres dipeptidyl peptidase-4 (DPP-4) los ntawm kev rhuav tshem nws, uas yog ib qho enzyme uas nquag nres incretin peptides los ntawm bioavailable. Cov kev tshawb fawb qhia tau hais tias bioglutide na-931's binding kinetics qhia cov receptors nyob tsis tu ncua.

Nrog rau kev sib cais cov nqi uas txhawb kev taw qhia kev ua haujlwm uas kav ntev.Qhov kev sib koom ua ke ntev dua no ua rau muaj kev ua kom qis qis qis dua piv rau incretin analogs nrog luv dua ib nrab- lub neej. Qhov no ua rau cov kws tshawb fawb muaj txiaj ntsig zoo rau kev saib mus rau hauv cov ncauj lus ntev - tswj cov metabolism hauv lub sijhawm.

Receptor Binding Dynamics thiab teeb liab Transduction

Thaum bioglutide na-931 txuas rau GLP-1 thiab GIP receptors, nws tso tawm ntau cov xwm txheej hauv cov hlwb uas koom nrog G-protein coupling thiab tsim cov cyclic AMP (cAMP). Cov molecule ua haujlwm zoo sib npaug ntawm ob hom receptors, yog li nws tsis muaj qhov ua kom tsis sib xws uas tuaj yeem txwv txoj kev kho mob ntawm ob lub agonists uas tsis zoo tsim.

Vim tias nws qhov kev ua kom sib luag sib luag, nws muaj txiaj ntsig zoo rau cov kev tshawb fawb uas saib seb ob txoj hauv kev metabolic tseem ceeb cuam tshuam li cas rau ib leeg. Cov qauv taw qhia teeb tsa los ntawm bioglutide na-931 yog qhov nyuaj dua li tsuas yog ua tus xa xov thib ob. Cov kev tshawb fawb tau pom tias qhov sib xyaw ua ke muaj kev cuam tshuam ntawm cov noob hloov pauv, tsim cov protein ntau, thiab hloov pauv ntawm cov cellular metabolic. Cov teebmeem no ua haujlwm ua ke los piav qhia qhov sib xyaw ua ke tag nrho cov txiaj ntsig metabolic. bioglutide na-931 yog ntau dua li cov receptor agonist vim nws muaj ntau yam sib txawvbioglutide na-931 teebmeem. Nws kuj hloov cov metabolism hauv txoj hauv kev uas muaj lub cev loj.

bioglutide na-931 GLP-1 thiab GIP Pathway Synergy

bioglutide na-931 muaj peev xwm kho tau ntau heev vim tias nws ua rau ob qho tib si GLP-1 thiab GIP txoj hauv kev tib lub sijhawm. Txhua lub cev incretin muaj nws cov teebmeem biochemical, tab sis thaum lawv ua haujlwm ua ke, lawv muaj cov teebmeem uas ntau dua li cov txiaj ntsig ntawm txhua txoj hauv kev tau txhawb nqa.

Ua tiav Metabolic Actions ntawm Dual Incretin Signaling

Kev ua haujlwm ntawm GLP-1 receptor feem ntau cuam tshuam rau cov piam thaj sib npaug los ntawm kev ua kom cov insulin tso tawm, txo qis glucagon tso tawm, thiab ncua lub plab khoob. Stimulating GIP receptors muaj cov txiaj ntsig zoo ntawm lub cev, xws li ua kom cov tshuaj insulin ua haujlwm zoo dua, ua kom nrawm nrawm ntawm cov rog, thiab muaj peev xwm tiv thaiv cov neurons. Thaum bioglutide na-931 tig rau ob lub tshuab tib lub sijhawm, lawv ua haujlwm ua ke los ua cov tshuaj tiv thaiv metabolic loj dua li ob txoj hauv kev tuaj yeem ua rau nws tus kheej.

Cov kev tshawb fawb uas tau saib rau hauv qhov kev sib xyaw no pom tau tias ua kom txoj hauv kev GIP tuaj yeem txhawb nqa qee qhov kev cuam tshuam zoo ntawm GLP-1 cov cim thaum muaj peev xwm txo qis qee qhov tsis zoo.Nws zoo li qhov sib xyaw ua haujlwm zoo dua GLP-1 agonism ib leeg kom nce qabzib-dependent insulin secretion. Qhov no qhia tau hais tias kev ua kom GIP receptors ua rau pancreatic beta hlwb rhiab heev rau GLP-1 stimulation. Ib qho txiaj ntsig loj ntawm dual-agonist molecules zoo li bioglutide na-931 yog tias lawv ua haujlwm ua ke.

Integrated Metabolic Regulation Los ntawm Dual Pathway Engagement

Siv bioglutide na-931 los txuas GLP-1 thiab GIP teeb liab ua rau cov txheej txheem metabolic ua kom tiav ntau dua hauv kev xav ntawm lub cev. Nws yog ib txwm ua rau ob qho tib si peptides ua hauj lwm ua ke los tsim cov tshuaj incretin tom qab noj mov, thiab dual -agonist compounds zoo dua li qhov kev koom tes hauv ntuj no dua li ib leeg -receptor therapeutics. Txoj kev biomimetic no yuav piav qhia tias yog vim li cas cov neeg uas noj ob lub agonists feem ntau muaj cov txiaj ntsig zoo hauv metabolic ntau dua li cov neeg uas tau txais kev cuam tshuam ib leeg. bioglutide na-931 muaj cov txiaj ntsig metabolic ntev ntev uas kav ntev tom qab thawj zaug koob tshuaj, raws li kev tshawb fawb uas saib cov qauv ntawm lub cev ntawm ob lub receptor kev ua haujlwm.

Yog vim li casbioglutide na-931 Koom Nrog Kev Tshawb Fawb Txog Zog Metabolism?

bioglutide na-931 tau siv rau hauv ntau cov kev tshawb fawb tshawb fawb los pab nrog lub zog metabolism. Cov kws tshawb fawb tab tom saib yuav ua li cas dual incretin activation cuam tshuam rau cov txheej txheem thermogenic, kev siv roj, thiab kev siv tag nrho lub cev. Cov tshuaj hloov ntau dua li cov calories uas koj noj. Nws ua qhov no los ntawm cov txheej txheem neuroendocrine nyuaj uas tswj hwm tus nqi metabolic thiab lub zog faib li cas.

Metabolic Rate Enhancement thiab Thermogenic Activation

Cov kev tshawb fawb hauv tsev kho mob tau pom tias muab bioglutide na-931 ua rau siv lub zog ntau dua, uas qhia tau tias cov txheej txheem thermal tau qhib. Muaj incretin receptors nyob rau hauv lub hypothalamus uas tswj cov metabolic tus nqi thiab peripheral paj hlwb kev ua si, yog li qhov kev txiav txim no zoo li yuav tsum tau kho nyob rau hauv ib feem ntawm lub hauv paus paj hlwb. Piv rau ib leeg -receptor agonists, dual-agonist profile yuav ua rau cov teebmeem metabolic, uas tswj tau los ntawm lub hlwb, muaj zog dua.

Muaj ob hom thermogenesis hauv cov tshuaj tiv thaiv bioglutide na-931: obligatory thermogenesis, uas ua rau lub zog rau lub cev ua haujlwm yooj yim, thiab facultative thermogenesis, uas ua rau cua sov thaum xav tau.Kev tshawb fawb tshiab qhia tias kev ua kom GIP receptors tuaj yeem ua lub luag haujlwm loj hauv kev ua haujlwm ntawm cov ntaub so ntswg adipose. Qhov no yog ib hom roj uas tso tawm lub zog raws li cua sov hloovbioglutide na-931khaws nws li triglycerides. Qhov kev nce hauv cov txheej txheem thermogenic no yog qhov hloov pauv zoo metabolically uas pab txhim kho lub zog sib npaug.

Substrate Siv Cov Qauv thiab Metabolic Flexibility

bioglutide na-931 hloov ntau dua li lub zog siv lub cev xwb. Nws kuj hloov cov roj qhov twg lub cev nyiam siv. Cov kev tshawb fawb pom tau hais tias cov neeg uas noj ob lub incretin agonists muaj kev hloov hauv lawv cov metabolism uas ua rau nws yooj yim dua. Piv txwv li, lawv hlawv roj ntau dua thiab siv cov carbohydrates tsawg. Vim qhov kev hloov pauv no, cov roj khaws cia tuaj yeem siv los ua lub zog siv tau zoo dua,

Nws yog ib qho tseem ceeb tshwj xeeb rau kev tshawb fawb txog lub cev. Cov metabolic yooj tau txuas nrog bioglutide na-931 zoo li txuas rau kev ua haujlwm mitochondrial zoo dua thiab nce insulin rhiab heev. Los ntawm kev txhim kho cov hlwb siv lub zog ntawm qib organellar, cov khoom ua rau ATP ntau npaum li cas thiab txo qis cov cim qhia kev ntxhov siab. Cov kev hloov pauv no ntawm qib cellular ua rau cov metabolism zoo dua thoob plaws hauv lub cev, uas cov kws tshawb fawb tuaj yeem ntsuas siv cov calorimetry tsis ncaj thiab substrate oxidation tests.

bioglutide na-931 Qab Zib Teeb Pom Kev thiab Kev Txhawb Lub Cev Lub Cev

Lwm qhov tseem ceeb ntawm txoj kev tshawb fawb bioglutide na-931 yog tswj kev tshaib plab thiab puv. Lub compound cuam tshuam rau ntau txoj hauv kev uas tswj kev tshaib kev nqhis los ntawm ob qho tib si peripheral thiab hauv nruab nrab cov txheej txheem. Qhov no ua rau kev npaj txo qis hauv kev noj zaub mov uas txhawb txoj kev kawm rau kev hloov lub cev muaj pes tsawg leeg.

Central Nervous System Appetite Regulation

bioglutide na-931 tuaj yeem hla cov ntshav- lub hlwb barrier nyob rau hauv ntau txoj kev. Nws kuj tig rau receptors ntawm peripheral qab haus huv uas tham nrog hypothalamus lub chaw tswj kev tshaib kev nqhis. Qhov kev tswj hwm ntawm kev tshaib kev nqhis no suav nrog kev hloov pauv neuropeptide signaling kom orexigenic (peptides ua rau koj tshaib plab) qeeb thiab anorexigenic (peptides uas ua rau koj hnov ​​​​qab) nce ntxiv. Dual -receptor activation profile tej zaum yuav zoo dua ntawm kev tswj kev tshaib kev nqhis dua li kev kho ib leeg. Cov kws tshawb fawb uas saib cov cwj pwm noj mov ntawm cov neeg uas noj bioglutide na-931 pom tias ob qho tib si qhov loj thiab zaus ntawm cov pluas noj tsawg.

Qhov no qhia tau hais tias cov tshuaj muaj kev cuam tshuam rau ob qho tib si satiation (xav tias thaum noj mov) thiab txaus siab (tsis xav tshaib plab thaum noj mov). Qhov kev hloov pauv tag nrho hauv kev qab los noj mov tsis zoo li yuav tsum tau nrog los ntawm kev nce hauv kev tshaib kev nqhis. Qhov no qhia tau hais tias qhov sib xyaw ua ke tuaj yeem rov pib lub cev kev noj qab haus huv cov txheej txheem es tsis yog ua rau tib neeg xav tias tag nrho ib ntus.

Lub cev sib xyaw hloov kho los ntawm kev sib xyaw ua ke

Cov kev hloov hauv lub cev muaj pes tsawg leeg pom nyob rau hauv txoj kev tshawb fawb bioglutide na-931 yog tshwm sim los ntawm kev sib xyaw ua ke ntawm cov teebmeem metabolic, xws li txo qis caloric kom tsawg, nce kev siv zog, txhim kho lipid oxidation, thiab tejzaum nws muaj kev cuam tshuam ncaj qha rau cov metabolism ntawm cov ntaub so ntswg adipose.

Cov kev tshawb fawb pom kev siv txoj hauv kev zoo li DEXA scanning thiab MRI tau pom tias cov ntaub so ntswg adipose txo ntau dua li lwm hom rog. Visceral adipose cov ntaub so ntswg yog hom rog uas yog metabolically teeb meem thiab txuas rau insulin tsis kam thiab metabolic tsis ua haujlwm. Qhov tseem ceeb, kev tshawb fawb qhia tau hais tias bioglutide na-931 tuaj yeem pab ua kom cov leeg nqaij ntshiv thaum lub sijhawm muaj zog tsis zoo. Qhov no yog ib qho tseem ceeb heev rau kev kawm txog lub cev muaj pes tsawg leeg. Cov tshuaj zoo li pab ua kom lub cev tsis muaj zog vim tias nws hloov pauv txoj kev cov proteins uas tawg thiab kuj tseem tuaj yeem ua haujlwm los ntawm kev cuam tshuam nrog kev loj hlob hormone system. Lub cev zoo bioglutide na-931Kev hloov kho cov qauv tsim rau kev siv metabolic yog ib qho uas cia koj poob rog thaum ua kom cov leeg nqaij.

Kev siv yav tom ntej ntawmbioglutide na-931 hauv Multi-Agonist Science

Kev tshawb fawb ntawm bioglutide na-931 nce zuj zus thaum cov kws tshawb fawb nrhiav kev siv tshiab dua li nws cov kev siv metabolic li ib txwm. Vim nws muaj peev xwm ua kom muaj ntau yam incretin receptors, lub compound tuaj yeem siv los kawm ntau yam ntawm lub cev, xws li lub plawv hlwb, lub raum cov qauv, thiab cov hlab ntsha.

Daim Ntawv Thov Kev Tshawb Fawb Txog Kab Mob

Cov ntaub ntawv tshiab qhia tau hais tias ua kom cov incretin receptors muaj lub plawv-kev noj qab haus huv uas yog cais los ntawm kev txhim kho metabolic. Txoj kev tshawb fawb bioglutide na-931 tau qhia tias nws yuav pab tau endothelial muaj nuj nqi, tswj ntshav siab, thiab cov metabolism hauv lub plawv. Cov teebmeem ntawm lub plawv tuaj yeem suav nrog kev ua ncaj qha rau cov leeg nqaij leeg thiab lub plawv myocytes los ntawm receptors, nrog rau cov txiaj ntsig thib ob los ntawm cov metabolism hauv lub cev zoo dua. Cov kws tshawb fawb tseem tab tom saib seb cov txiaj ntsig ntawm lub plawv ua haujlwm li cas.

Tab sis lawv zoo li muaj kev cuam tshuam los tiv thaiv - txoj hauv kev inflammatory, txo qis oxidative kev nyuaj siab, thiab ua rau nitric oxide ntau bioavailable.bioglutide na-931 yog ib qho cuab yeej muaj txiaj ntsig rau kev nkag siab txog cov metabolic-cardiovascular interface thiab yuav ua li cas cov kev kho mob metabolic cuam tshuam rau cov hlab plawv. Nws tuaj yeem siv rau hauv cov kev tshawb fawb uas saib cov kab mob plawv.

Combination Therapy Research thiab Triple Agonist Development

Tib neeg tam sim no txaus siab rau ntau qhov nyuaj ntau- cov hom phiaj receptor vim yog kev ua tiav ntawm ob-cov tshuaj agonist.

Cov kws tshawb fawb tab tom saib seb puas ntxiv bioglutide na-931 rau lwm cov tshuaj metabolic modulators ua rau cov teebmeem muaj zog dua lossis yog tias lawv ua haujlwm zoo ua ke. Lawv kuj tseem tab tom saib seb puas yog tom ntej no - tiam triple agonists uas suav nrog glucagon receptor activation yuav muaj txiaj ntsig ntau dua. Vim tias cov lus qhia no rau kev sib xyaw ua ke thiab kev tshawb fawb ntau tus agonist, bioglutide na-931 yog ob qho tib si siv tau rau kev kawm hauv nws daim ntawv tam sim no thiab txoj hauv kev kom tau txais kev kho mob ntau dua.

Xaus

Bioglutide na-931yog ib kauj ruam loj rau pem hauv ntej hauv ntau-kev tshawb fawb metabolic. Nws ua rau cov kws tshawb fawb muaj txoj hauv kev zoo los saib seb GLP-1 thiab GIP txoj kev qhia txog kev sib cuam tshuam li cas. Qhov sib xyaw ua ke sib npaug ntawm ob- agonist xwm muaj cov teebmeem metabolic uas ua haujlwm ua ke los hloov lub cev qauv, lub zog metabolism, thiab tejzaum nws cov hlab plawv thiab neural systems. bioglutide na-931 yog siv rau hauv ntau thiab ntau txoj haujlwm tshawb fawb raws li peb kawm ntxiv txog seb incretins ua haujlwm li cas thiab nrhiav cov hom phiaj kho tshiab. Rau cov tuam txhab tshuaj, cov koom haum biotechnology, CDMOs, thiab cov chaw tshawb fawb, kev nkag mus rau qib siab -purity bioglutide na-931 nrog cov ntaub ntawv txheeb xyuas dav dav sawv cev rau lub hauv paus tseem ceeb rau kev nce qib kev tshawb fawb txog metabolic thiab txhim kho tom ntej - tiam neeg sib tw kho mob. Ntau-kev tshawb fawb agonist muaj lub neej yav tom ntej uas ci ntsa iab ua ntej, thiab bioglutide na-931 yog cov cuab yeej siv tau zoo rau cov kws tshawb fawb thiab cov ntaub ntawv pov thawj-ntawm-lub tswv yim rau ntau qhov kev txhawb nqa ntau hom phiaj. Nws muaj peev xwm hais tias raws li kev tshawb fawb txuas ntxiv mus, qhov sib xyaw no yuav pab cov kws tshawb fawb tsim cov kev tshawb pom tseem ceeb txog seb cov metabolism ua haujlwm li cas thiab pab lawv tuaj nrog txoj hauv kev tshiab los kho cov kab mob metabolic.

FAQ

Koom Tes Nrog BLOOM TECH rau hwmbioglutide na-931 khoom

Nrhiav kev vam meejbioglutide na-931tus kws kho mob uas paub yuav ua li cas thiaj li nyuaj peptides thiab ua raws li cov cai tseem ceeb heev rau kev ua tiav ntawm koj cov haujlwm tshawb fawb. BLOOM TECH tau ua cov kws tshuaj -qib bioglutide na-931 rau ntau tshaj 12 xyoo thiab muaj GMP- ntawv pov thawj kev tsim muaj peev xwm (US-FDA, EU, JP, CFDA) kom xa cov tshuaj-qib bioglutide na-931 uas ua tau raws li cov tuam txhab tshuaj, kev tshawb fawb txog kev lag luam, thiab cov koom haum tshawb fawb.

Peb qhov kev lees paub zoo tshaj plaws siv peb theem kev kuaj xyuas zoo: kev sim hauv cov nroj tsuag, tshuaj xyuas los ntawm peb lub tuam txhab QA / QC, thiab kev tshuaj xyuas los ntawm peb tus neeg thib peb- txoj cai. Qhov no ua kom paub tseeb tias txhua pawg ntawm bioglutide na-931 ua tau raws li qhov koj xav tau. Peb muab cov ntaub ntawv tshawb fawb ua tiav, suav nrog HPLC, huab hwm coj spectrometry, thiab batch-specific CoA los txhawb koj cov kev tshawb fawb txog kev tsim tawm thiab kev tswj xyuas. Nrog rau peb cov qauv tus nqi pob tshab, lav lub sijhawm ua haujlwm, thiab pab pawg kev pabcuam kev tshaj lij, BLOOM TECH muab cov kev ntseeg siab thiab kev txawj ntse uas koj xav tau cov kev tshawb fawb metabolic.

Hu rau peb pab neeg tshawb fawb niaj hnub no los tham txog koj cov bioglutide na-931 cov cai thiab tshawb nrhiav seb peb qhov kev pabcuam ib-nres tuaj yeem ua kom koj cov sijhawm tshawb fawb tau nrawm dua thaum tswj cov qauv zoo tshaj plaws. Hu rau peb ntawmSales@bloomtechz.comthov cov khoom specifications, nqe lus hais, thiab kev sab laj rau koj qhov project tom ntej.

Cov ntaub ntawv

1. Frias JP, Nauck MA, Van J, et al. Kev ua tau zoo thiab kev nyab xeeb ntawm dual GIP thiab GLP-1 receptor agonism hauv kev tswj cov kab mob metabolic. Lancet Diabetes & Endocrinology. 2021;9(10):653-665.

2. Holst JJ, Rosenkilde MM. GIP raws li lub hom phiaj kho mob ntshav qab zib thiab rog rog: kev pom los ntawm incretin co-agonists. Phau ntawv Journal of Clinical Endocrinology & Metabolism. 2020;105(8):e2710-e2716.

3. Müller TD, Finan B, Bloom SR, et al. Glucagon-zoo li peptide 1 thiab qabzib-nyob ntawm insulinotropic polypeptide receptor co-agonism rau kev kho kab mob metabolic. Molecular Metabolism. 2019; 30:194-216.

4. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cov kev ua ntawm lub plawv thiab cov txiaj ntsig kev kho mob nrog ob thiab tri-agonist incretin-raws li kev kho mob. Kev xa tawm . 2022; 146(4): 321-338.

5. Samms RJ, Cosgrove R, Snook ER, et al. GIPR agonism kho qhov hnyav-kev ywj pheej ntawm insulin rhiab heev los ntawm dual GIP / GLP-1 receptor agonists. Molecular Metabolism. 2021; 48:101219.

6. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide yog ib qho kev tsis sib haum xeeb thiab tsis ncaj ncees dual GIP thiab GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532